A new study reports a promising cancer treatment strategy using a peptide called 1H13, designed to target survivin—a protein that helps cancer cells avoid death. Survivin is highly expressed in tumors but largely absent in normal adult tissues, making it an attractive therapeutic target. Previous attempts to block survivin have had limited success, but this new approach uses a multi-functional peptide to overcome those challenges.
The 1H13 peptide works by disrupting several critical functions of survivin at the same time. It blocks protein pairing, releases cell death signals, interferes with cell division, and prevents survivin from reaching key locations in the cell. Researchers also engineered the peptide to act in different cellular compartments, triggering apoptosis in the cytosol and mitochondria while causing division failure in the nucleus. A modified version improves stability and resistance to degradation.
In laboratory studies, the peptide showed strong anti-cancer effects across multiple cell lines. In mouse lung cancer models, it reduced tumor size by more than 90%, with the nuclear-targeted version proving most effective. Early data also suggests it may enhance immune response, supporting future combination with immunotherapy.
窗体顶端
窗体底端